The agreement provides Virxsys with rights to utilise this technology in the production process of Virxsys’s anti-HIV/AIDS product VRX496 which is currently in Phase II trials.
Under the agreement, Oxford BioMedica receives an upfront licence fee and annual maintenance payments.
In addition, Oxford BioMedica will receive payments on the achievement of clinical and regulatory milestones by Virxsys and product royalties.
Oxford BioMedica’s CEO, Professor Alan Kingsman, said, "We are delighted to welcome Virxsys to the growing list of Oxford BioMedica’s technology licensees. This agreement further underlines the breadth and strength of our proprietary gene delivery technologies."